Search 

Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.

Distributer for pharmaceutical products

Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

• EpimAb Biotherapeutics is a biopharmaceutical R&D company based in Shanghai creating a pipeline of novel biologics focused around oncology and other disease areas of high value to patients using its a proprietary, and unique technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). Company’s pioneer product EMB-01 is a bispecific antibody based on FIT-Ig platform targeting EGFR as well as c-MET, currently is in being investigated for treatment of solid tumors in global Phase I/II clinical trial. EpimAb aims to commercialize its FIT-Ig technology as broadly as possible and maximize the number of programs based on the platform. Further information please visit www.epimab.com
• 岸迈生物科技有限公司是一家总部位于上海的生物制药研发公司。公司基于自主研发的FIT-Ig®双特异性抗体平台技术,聚焦于肿瘤IO领域的创新药品开发。公司的先锋产品EMB-01是一种基于FIT-Ig®平台的双特异性抗体,针对EGFR和c-MET靶点,目前正在进行针对实体瘤的全球I/II期临床试验。岸迈生物的目标是尽可能广泛地将其FIT-Ig®技术商业化,并最大限度地拓展基于该平台的新药开发。更多信息,请访问公司官网www.epimab.com。

ExoProTher Medical is an Israeli pre-clinical stage company developing a novel biotherapy for cancer treatment, relevant to all cancers with p53 mutation or inactivation - more than 60% of human cancers. Our technology is unique and disruptive and is fully owned by the company.

The company has been funded by private investors. We are currently working on shaping our next funding round.

FEBICO's current major development of new drug focuses on the treatment of global emerging infectious diseases and hepatitis-related diseases.

1.  Influenza

FEBICO’s Apomivir obtained the approval of US (IND120123) and Taiwan INDs application in 2013 and 2014, respectively. In previous experiments, FB-1603, the active pharmaceutical ingredient of Apomivir, was found to inhibit a variety of viruses in cellular experiments, including influenza A/H1N1, A/H3N2, influenza B, novel influenza viruses (2009), and influenza viruses resistant to tamiflu. Animal experiments have shown oral administration of FB-1603 can effectively reduce the mortality rate of mice caused by influenza A. Apomivir® is designed as oral capsule and given to patients infected with influenza within 48 hours of confirmed infection. The primary outcome measures the time reaching afebrile compared to the control group.

2. COVID-19 (SARs-CoV-2)

The new coronavirus hit the world in 2020, causing tens of millions infections and millions of deaths. In addition to the typical clinical pathology includes respiratory symptoms, severe patients will progress to severe pneumonia, acute respiratory distress syndrome (ARDS) or multiple organ failure, shock or even death. Therefore, the threat is quite big.FB-1603 has been proven in cellular and animal experiments to effectively reduce inflammation and accelerate the healing of scarred tissues. It has also been found in cellular experiments to inhibit pulmonary fibrosis. Because FB-1603 is the active pharmaceutical ingredient of Apomivir. Previous IND 120123 documents and new cellular data against COVID-19 were used to file a pre-IND (151566).

3. Treat liver damage

Current available treatments for liver cancer include surgical resection, liver transplantation, local destruction therapy, transarterial chemoembolization (TACE), chemotherapy and targeted therapy. However, according to clinical literature statistics, about 10% of patients treated with surgical resection or TACE will have postoperative complications such as deterioration of liver function (increased AST/ALT), jaundice, liver failure, and leads to 5% mortality rate. However, there are no effective preventive measures or therapeutic drugs to reduce the incidence of postoperative liver injury. In early phase of clinical trials, it has been observed that FB-1603 help the improvement of patients' liver function after hepatectomy or chemoembolization therapy.

4. Treat Herpes Virus

Herpes virus is a common infectious virus. Depending on the type of virus, it can cause redness and swelling of the skin on the lips or external genitals, resulting in blisters and ulcers, causing stinging and discomfort. Once infected with the herpes virus, the virus will be permanently latent in the human ganglion, and will repeatedly attack when the immune system is weakened. FB1706 has been proven in cellular study to effectively inhibit herpes type 1 and type 2 viruses with a very low dose, and some data show that topical application can shorten the course of the individual’s disease and accelerate the recovery time. The animal module for the herpes virus is currently under establishment. We expect to complete the animal studies before June 2021 and complete documentation of toxicology study and CMC (Chemistry, manufacturing, and control) report.

5. Liver fibrosis treatment

In the past, liver disease was considered a national disease in Asian community. So far, about 10,000 people in Taiwan are diagnosed with liver cancer and 7,700 people die from liver cancer every year. It still ranks as third in cancer incidence and second in mortality. Therefore, chronic liver disease cannot be underestimated. A familiar trilogy is liver inflammation, cirrhosis, and finally liver cancer.

The major cause is that when liver cells are damaged for a long time, liver tissue is formed into fibrosis, leads to hardening of liver, i.e. cirrhosis. Therefore, the key to treatment is to slow down the formation of fibrosis. Currently there is no approved drug to treat liver fibrosis in the world. FB-1807 has been observed in early phase of clinical trials to effectively reduce the liver fibrosis index of liver cancer patients. Preclinical study includes identification of active ingredient and animal studies are currently underway.

 6. Cure Hepatitis B

Chronic hepatitis B virus (HBV) infection is still an important issue of global health, causing nearly one million people die every year from major complications of liver cirrhosis and liver cancer. In recent years, the natural history of HBV and the replication mechanism have been clearly studied. Therefore, it is very important to know how to completely eliminate the virus to prevent viral infection. Although many different drugs have been developed to treat HBV, the long-term use of existing drugs is a heavy burden but still cannot achieve a complete cure. Therefore, a new generation of anti-viral medication is still needed.

FB-1808 has been observed in early clinical trials with significant anti-virus effects. We have confirmed the active ingredient and mechanism study is still ongoing.

At FJS Biopharmaceutical Inc., we combine technological innovation with world class process excellence. These enable our customers to deliver their discoveries. In our extensive contract development services portfolio we use advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins.

Changes in the global marketplace are quickly altering the demands on biopharmaceutical manufacturing facilities. we have changed to Continuous Manufacturing Processes design that is cost-effective, flexible and responsive to a diversified product line. Continuous manufacturing processes offers a number of advantages:
1. More agile and flexible, and can therefore respond more rapidly to changes in supply or demand.
2. Reducing or eliminating scale-up bottlenecks could also help to accelerate the path to market for breakthrough
pharmaceuticals.
3. More efficient, reliable and cost-effective than traditional batch methods, resulting in significant cost savings down the line.
4. Producing smaller environmental footprint and reduce the risk of product quality failures compared to batch systems.
5. Supports a systematic, scientific and risk-based approach to pharmaceutical development. Development of a robust
process relies on utilizing the acquired product and process understanding to identify sources of variation to product quality
and to design appropriate control strategies to address these risk areas.
6. provides an opportunity to utilize this enhanced product and process understanding to adopt advanced manufacturing
controls and to produce uniformly high-quality products with reduced waste resulting from the generation of out-of-
specification material.

We are a preferred global partner to the Biopharmaceutical, biotech and specialty ingredients markets. Our solutions improve life quality by preventing illness, enabling healthier lifestyles and supporting a safe environment.

Real-time Data Aggregation and analytics in real-time

We support companies gather information and analyze information in real-time speed access to insight facts and evidence into suppliers, vendors. partners and customers

Focus-X is a preclinical stage biotech company committed to the discovery and development of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.